Avanos Medical, Inc.
HealthcareNYSE:AVNS · New York Stock Exchange
-$0.02 today
Vol 0.31M · Avg 1.51M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$715.9M of revenue converted into -$69.4M of net income for the selected period. Gross margin is 48.6% and net margin is -10.0%, showing how much revenue survives after costs and taxes. EPS is $-1.50, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $701.2M +1.9% | $687.8M +2.2% | $673.3M -1.6% | $684.1M -8.1% | $744.6M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $352.2M +14.9% | $306.5M +4.4% | $293.6M +1.3% | $289.9M -20.5% | $364.7M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $349.0M -8.5% | $381.3M +0.4% | $379.7M -3.7% | $394.2M +3.8% | $379.9M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 49.8% -5.7pp | 55.4% -1.0pp | 56.4% -1.2pp | 57.6% +6.6pp | 51.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $23.1M -11.8% | $26.2M -3.7% | $27.2M -11.1% | $30.6M -5.3% | $32.3M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $218.3M -30.7% | $315.1M +9.6% | $287.5M -11.0% | $323.1M +23.9% | $260.8M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $410.6M +20.3% | $341.3M +8.5% | $314.7M -10.7% | $352.3M +20.2% | $293.1M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $29.0M -36.3% | $45.5M +4.6% | $43.5M +5.8% | $41.1M +7.3% | $38.3M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$33.2M +90.4% | -$345.6M -783.0% | $50.6M -35.0% | $77.8M +59.1% | $48.9M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -4.7% +45.5pp | -50.2% -57.8pp | 7.5% -3.9pp | 11.4% +4.8pp | 6.6% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$61.6M -254.0% | $40.0M -38.5% | $65.0M +55.1% | $41.9M -51.7% | $86.8M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -8.8% -14.6pp | 5.8% -3.8pp | 9.7% +3.5pp | 6.1% -5.5pp | 11.7% | 16.6% | 24.1% | 22.0% |
| Interest Income | $3.2M -37.3% | $5.1M +75.9% | $2.9M +141.7% | $1.2M +500.0% | $200.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $4.0M -67.2% | $12.2M -18.7% | $15.0M +50.0% | $10.0M +203.0% | $3.3M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$4.6M +99.0% | -$443.3M -508.1% | -$72.9M -379.6% | -$15.2M +80.9% | -$79.5M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$66.2M +83.6% | -$403.3M -5005.1% | -$7.9M -129.6% | $26.7M +265.8% | $7.3M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -9.4% +49.2pp | -58.6% -57.5pp | -1.2% -5.1pp | 3.9% +2.9pp | 1.0% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $1.7M +110.0% | -$17.0M -950.0% | $2.0M -61.5% | $5.2M +420.0% | $1.0M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$67.9M +82.7% | -$392.1M -534.5% | -$61.8M -222.4% | $50.5M +701.6% | $6.3M | $4.9B | $4.8B | $4.7B |
| Net Margin | -9.7% +47.3pp | -57.0% -47.8pp | -9.2% -16.6pp | 7.4% +6.5pp | 0.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +82.9% | -$9 -541.4% | -$1 -223.1% | $1 +730.8% | $0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +82.9% | -$9 -541.4% | -$1 -224.3% | $1 +723.1% | $0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $46.4M +0.9% | $46.0M -1.3% | $46.6M -0.6% | $46.9M -2.5% | $48.1M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $46.4M +0.9% | $46.0M -1.3% | $46.6M -1.5% | $47.3M -2.7% | $48.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
CeriBell, Inc.
NASDAQ:CBLL
$700.80M
Bioventus Inc.
NASDAQ:BVS
$576.54M
Cytek Biosciences, Inc.
NASDAQ:CTKB
$511.40M
Varex Imaging Corporation
NASDAQ:VREX
$464.78M
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
$461.60M
Community Health Systems, Inc.
NYSE:CYH
$439.66M
Pacific Biosciences of California, Inc.
NASDAQ:PACB
$406.89M
ClearPoint Neuro, Inc.
NASDAQ:CLPT
$403.06M
Standard BioTools Inc.
NASDAQ:LAB
$346.53M
Bicycle Therapeutics plc
NASDAQ:BCYC
$281.05M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does AVNS generate?
Avanos Medical, Inc. (AVNS) reported $701.20M of revenue in fiscal 2025.
Is AVNS profitable?
Avanos Medical, Inc. (AVNS) reported -$67,900,000.00 of net income, with a net margin of -9.7%.
Explore More
Continue the stock analysis
Jump to another research area for this company.